 Establishes NeoGenomics as a technology leader in the minimal residual disease MRD testing market NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for 390 million Completes 200 million strategic financing with leading oncology-focused specialist investors FT. MYERS, FL ACCESSWIRE May 5, 2021 NeoGenomics, Inc. NASDAQ:NEO, a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has agreed to acquire Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England. 